Tivic Health Systems 주식 (NASDAQ: TIVC)

에 대한 최신 뉴스 Tivic Health Systems (NASDAQ:TIVC) 주식

Tivic Health Systems

Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems Inc

Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) sees FY2025 sales of $3.000 billion-$3.400 billion vs $3.21 billion analyst estimate.

News

Guidance

TROX

Tronox Holdings Sees FY2025 Sales $3.000B-$3.400B vs $3.21B Est

Air T (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRT#NASDAQ">AIRT</a>) reported quarterly losses of $(0.47) per share. This is a 55.66 percent increase over losses of $(1.06) per share from the same period last year. The company reported $77.88 million in sales this quarter. This is a 22.15 percent increase over sales of $63.76 million the same period last year.

Earnings

AIRT

Air T Q3 EPS $(0.47) Up From $(1.06) YoY, Sales $77.88M Up From $63.76M YoY

TSLA MOVED UP OVER 9 POINTS AT ITS HIGH POINT OF THE DAY
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="796" height="634" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/12210715/Screen-Shot-2025-02-12-at-4.12.46-PM.png" alt="" class="wp-image-5733" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/12210715/Screen-Shot-2025-02-12-at-4.12.46-PM.png 796w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/12210715/Screen-Shot-2025-02-12-at-4.12.46-PM-300x239.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/12210715/Screen-Shot-2025-02-12-at-4.12.46-PM-768x612.png 768w" sizes="(max-width: 796px) 100vw, 796px" /></figure>
TESLA, Inc. (TSLA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:13 AM on February 12th, a significant trading signal occurred for Tesla, Inc. (TSLA) as it demonstrated a Power Inflow at a price of $334.45. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Tesla&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Tesla&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $334.45 The returns on the High price ($346.30) and Close price ($336.53) after the Power Inflow were respectively 3.5% and 0.6%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the TradePulse data showed a reversal at the point the stock turned down in the last 1/2 hour of trading.
Past Performance is Not Indicative of Future Results

Equities

Technicals

TRADEPULSE POWER INFLOW ALERT: TESLA (TSLA) MOVES 3.5% HIGHER AFTER ALERT FROM TRADEPULSE

The Company expects to recognize restructuring charges in connection with the workforce reduction plan, including severance, outplacement services, and benefits continuation.
It estimates that the foregoing charges will range between $1.8 million to $2.0 million, and expects the charges will be recognized and paid primarily in the first quarter of 2025. The substantial majority of these charges will result in cash expenditures, and the reduction in workforce plan is expected to be substantially complete by the end of the first quarter of 2025.&nbsp;
Annual pre-tax savings are estimated to be approximately $4.0 million, which the Company expects to realize beginning primarily in the second quarter of 2025 and beyond.

BZFD

BuzzFeed Expects Reduction In Workforce To Streamline Its News Operations For HuffPost;  Estimates Annual Pre-tax Savings To Be Approximately $4M

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) Q1 expected to be more than $(0.18) vs $0.07 Est. sees Q1 sales of $75.000 million-$95.000 million vs $104.22 million analyst estimate.

ASPN

Aspen Aerogels Q1 EPS expected to be more than $(0.18) vs $0.07 Est; Sees Q1 Sales $75.000M-$95.000M vs $104.22M Est

Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii.

Biotech

General

CSTL

Castle Biosciences To Share Data Reinforcing The Clinical Value Of Its Dermatologic Portfolio Of Gene Expression Profile Tests At The 22nd Annual Winter Clinical Dermatology Conference Feb. 14-19

BuzzFeed Plans To Reduce Expenses By Implementing An Approximately 5% Reduction In Current Workforce - Filing

Radian Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDN#NYSE">RDN</a>) announced today its plans to continue the return of capital to stockholders through an increased quarterly dividend. The company's Board of Directors approved a quarterly dividend of $0.255 per share, an increase of 4.1 percent from the previous quarterly dividend. The dividend is payable on March 11, 2025, to stockholders of record as of February 24, 2025. This marks the sixth consecutive year that the company has raised its quarterly dividend, which has more than doubled over the past five years.

Dividends

Radian Announces Quarterly Dividend Of $0.255 Per Share

SunLink Health Systems Q2 EPS $(0.19) Down From $(0.44) YoY; Revenue $7.935M Down From $8.510M YoY

WINV

WinVest Acquisition Extends Business Combination Deadline To March 17, 2025

Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) sees FY2025 sales of $9.450 billion-$9.600 billion vs $9.58 billion analyst estimate.

Waste Connections Sees FY2025 Sales $9.450B-$9.600B vs $9.58B Est

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.08 by 75 percent. This is a 1500 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $123.09 million which beat the analyst consensus estimate of $120.80 million by 1.89 percent. This is a 46.15 percent increase over sales of $84.22 million the same period last year.

Earnings Beats

Aspen Aerogels Q4 EPS $0.14 Beats $0.08 Estimate, Sales $123.09M Beat $120.80M Estimate

Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.05 by 40 percent. This is a 107.89 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $676.00 million which missed the analyst consensus estimate of $697.31 million by 3.06 percent. This is a 1.46 percent decrease over sales of $686.00 million the same period last year.

Earnings Misses

Tronox Holdings Q4 Adj $0.03 Misses $0.05 Estimate, Sales $676.00M Miss $697.31M Estimate

US Global Investors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROW#NASDAQ">GROW</a>) reported quarterly losses of $(0.01) per share. This is a 111.11 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $2.23 million in sales this quarter. This is a 20.83 percent decrease over sales of $2.82 million the same period last year.

GROW

US Global Investors Q2 EPS $(0.01) Down From $0.09 YoY, Sales $2.23M Down From $2.82M YoY

Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) reported quarterly earnings of $1.16 per share which missed the analyst consensus estimate of $1.20 by 3.33 percent. This is a 4.5 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $2.26 billion which beat the analyst consensus estimate of $2.25 billion by 0.65 percent. This is a 11.00 percent increase over sales of $2.04 billion the same period last year.

Waste Connections Q4 Adj $1.16 Misses $1.20 Estimate, Sales $2.26B Beat $2.25B Estimate

ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula.
The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well ahead of the 2027 deadline for Class III devices. In addition, the updated certification has extended the shelf life of the SmartFlow Cannula to 48 months in the European Union (EU), an increase from the prior shelf life of 24 months.

Global

CLPT

ClearPoint Neuro Announces European Medical Device Regulation Certification For The SmartFlow Cannula

Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.08 by 8.17 percent. This is a 6.64 percent decrease over earnings of $2.41 per share from the same period last year. The company reported quarterly sales of $258.030 million which beat the analyst consensus estimate of $257.849 million by 0.07 percent. This is a 8.11 percent increase over sales of $238.679 million the same period last year.

Kadant Q4 2024 Adj. EPS $2.25 Beats $2.08 Estimate, Sales $258.030M Beat $257.849M Estimate

WIIM

AMWL

American Well shares are trading lower after the company cut its FY25 revenue guidance and issued Q1 revenue guidance below estimates.

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares are soaring after the company reported its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43674593/dutch-bros-inc-reports-fourth-quarter-and-fiscal-year-2024-financial-results">highlights from the quarter.&nbsp;</a>
The Details:&nbsp;Dutch Bros reported quarterly earnings of&nbsp;7 cents&nbsp;per share which beat the analyst consensus estimate of&nbsp;2&nbsp;cents. Quarterly revenue came in at&nbsp;$342.8 million&nbsp;which beat the analyst consensus estimate of&nbsp;$317.8 million and is an&nbsp;increase over revenue of&nbsp;$254.12 million&nbsp;from the same period last year.
Dutch Bros opened 32 new shops, 25 of which were company-operated, during the fourth quarter. Company-operated shop revenues increased 38.2% to $314.2 million, as compared to $227.4 million in the same period of 2023.
Read Next: <a href="https://www.benzinga.com/25/02/43667841/inflation-is-hot-and-getting-hotter">Inflation Runs Hot In January: &#8216;Houston We Have A Problem,&#8217; Experts Warn</a>&nbsp; 
&#8220;We delivered exceptional performance in the fourth quarter as we ended 2024 on a high note. In the quarter, we drove an impressive 35% revenue growth and system same-shop sales growth of 6.9%. We believe our brand is resonating with customers, as we delivered 2.3% system same-shop transaction growth, the largest year-over-year increase in over two years,&#8221; said Christine Barone, CEO of Dutch Bros.
Outlook:&nbsp;Dutch Bros now sees fiscal 2025 revenue in a range of $1.55 billion to $1.57 billion. and total system shop openings&nbsp;in 2025 are estimated to be at least 160.&nbsp;
BROS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Dutch Bros shares are up 22.86% after hours at $79.36 Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Courtesy of Dutch Bros Inc.

Restaurants

Movers

BROS

Dutch Bros Stock Rallies After Blockbuster Q4 Results: Details

Waste Connections Q4 2024 Adj. EPS $1.16 Misses $1.20 Estimate, Sales $2.260B Beat $2.245B Estimate

Tivic Health names Lisa Wolf as interim CFO

Tivic Health Systems ( ($TIVC) ) just unveiled an announcement. Tivic Health Systems, Inc. has entered into an agreement with Maxim Group LLC to po...

Tivic Health Systems Initiates Stock Sale and Leadership Transition

FOXO Technologies, Tivic Health Systems, and Northann Corp. are the 3&nbsp;Penny Stocks&nbsp;to watch on November 12, 2024, based on&nbsp;TipRanks'...

3 Penny Stocks to Watch Now, 11/12/24

Tivic Health (TIVC) announced that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vag...

Tivic completes enrollment in vagus nerve stimulation device optimization study

Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript

Tivic Health Systems, Inc. ( ($TIVC) ) has released its Q3 earnings. Here is a breakdown of the information Tivic Health Systems, Inc. presented to...

Tivic Health Systems Reports Third Quarter 2024 Results

Tivic Health Systems GAAP EPS of -$0.23, revenue of $126K

Tivic Health Systems ( ($TIVC) ) has shared an update. Tivic Health Systems has shown notable advancements in its commercial business and its entry...

Tivic Health Systems Advances in VNS and ClearUP 2.0

Tivic Health Systems ( ($TIVC) ) has issued an announcement. On February 11, 2025, Tivic Health Systems entered into an exclusive licensing agreeme...

Tivic Health Systems Secures Licensing Agreement with Statera

Tivic Health (TIVC) announced it has acquired worldwide exclusive license rights from Statera Biopharma (STAB) to the late-stage Toll-like Receptor...

Tivic Health acquires exclusive rights to Entolimod from Statera BioPharma

FOXO

STAB

TIVC

Press Releases

Tivic Health Accelerates VNS Commercial Strategy Development

Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

First Subject Enrolled in Tivic Health's Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

Tivic Health Validates European Patents in Great Britain, Germany, and France

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

CEO Letter to Shareholders Issued by Tivic Health

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Autonomix Medical

Avinger

Bluejay Diagnostics

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

LogicMark

NanoVibronix

NAYA Biosciences

ENDRA Life Sciences

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Techs

Tenon Medical

Venus Concept

Catheter Precision

Tivic Health Systems shares are trading higher after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.

Comments

Tivic Health Systems

뉴스

에 대한 최신 뉴스 Tivic Health Systems (NASDAQ:TIVC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌